Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States

Overview of attention for article published in PharmacoEconomics, November 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (73rd percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

policy: 1 policy source
twitter: 5 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 37 Dimensions

Readers on

mendeley: 49 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy : Committee papers

Cited by National Institute for Health and Care Excellence on 08 Jan 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.